RRA
RIGL icon

Round Rock Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Round Rock Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$237K Buy
8,754
+9
+0.1% +$302 0.04% 291
2025
Q4 		$375K Buy
+8,745
New +$330K 0.06% 243

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Round Rock Advisors's RIGL Position: Q1 2026 in Review

Round Rock Advisors increased its Rigel Pharmaceuticals (RIGL) stake by 0.1% in Q1 2026, buying an estimated $302 and bringing the position to 8,754 shares worth $237K. The position accounts for 0.04% of the portfolio, ranked #291.

Round Rock Advisors first reported a position in RIGL in Q4 2025 and has held it in 2 quarters since. The position peaked at $375K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Round Rock Advisors held 8,754 shares of Rigel Pharmaceuticals worth $237K as of Q1 2026.
  • Round Rock Advisors bought 9 Rigel Pharmaceuticals shares in Q1 2026, an estimated $302.
  • Rigel Pharmaceuticals made up 0.04% of Round Rock Advisors's portfolio in Q1 2026, its #291 holding.
  • Round Rock Advisors first reported a position in Rigel Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Round Rock Advisors's Rigel Pharmaceuticals position peaked at $375K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Round Rock Advisors's 13F filing for Q1 2026, filed 15 May 2026.